Physician

Vinaya Potluri, M.D.

According to 2025 Medicare claims, Vinaya Potluri, M.D. (NPI: 1881647493) practices hematology/oncology in the Fort Worth-Arlington-Grapevine, TX market, with the plurality of this provider's patient population coming from Johnson, TX. This provider's primary affiliated billing organization is ONCOLOGY-HEMATOLOGY CONSULTANTS PA (NPI: 1629021159; TIN: 752512142) and primary practice location at 76028-7220. Potluri is affiliated with the UT Southwestern Accountable Care Network (ACO ID: D0211), participating under the REACH model.

Potluri's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 380 traditional Medicare patients, billed 93,793 HCPCS/CPT codes, and received $1,350,018 in Medicare payments. The top billing code was 99215 (Established patient office or other outpatient visit with high level of medical decision making, if using time, 40 minutes or more). Part D data shows 895 prescription claims across 191 beneficiaries totaling $2,022,396 in drug costs, led by Revlimid (Lenalidomide). 2020 DME data shows 68 claims. Open Payments data shows 13 records totaling $289. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing did not follow a clear longitudinal pattern. Concurrently, Part D prescription costs have moved from a lower plateau to a higher plateau, from $435,490 to $2,022,396. For DME billing, this provider has fewer than 5 years of reported data, so a reliable trend cannot be assigned.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	514	101,221	$1,250,288
2016	558	106,759	$1,204,860
2017	505	106,378	$1,264,513
2018	438	101,141	$1,706,982
2019	464	110,534	$1,915,945
2020	366	115,567	$1,897,055
2021	382	138,230	$1,854,367
2022	387	135,536	$1,262,071
2023	348	142,212	$1,358,137
2024	380	93,793	$1,350,018

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	113	677	$435,490
2016	129	682	$744,338
2017	121	844	$665,759
2018	126	805	$718,953
2019	143	927	$810,880
2020	163	955	$1,061,008
2021	168	866	$1,019,892
2022	164	699	$1,246,535
2023	172	735	$1,324,807
2024	191	895	$2,022,396

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	N/R	46	$3,267
2016	N/R	N/R	N/R
2017	N/R	33	$10,561
2018	N/R	N/R	N/R
2019	N/R	60	$7,103
2020	N/R	68	$4,690
2021	N/R	N/R	N/R
2022	N/R	N/R	N/R
2023	N/R	N/R	N/R
2024	N/R	N/R	N/R

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
99215	Established patient office or other outpatient visit with high level of medical decision making, if using time, 40 minutes or more	91	302	$131
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	205	408	$91
99213	Established patient office or other outpatient visit with low level od decision making, if using time, 20 minutes or more	115	154	$61
96365	Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less	54	95	$48
G2211	Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's	146	197	$13

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Revlimid	Lenalidomide	40	1,092	$695,243
Pomalyst	Pomalidomide	25	665	$387,951
Calquence	Acalabrutinib Maleate	14	420	$193,500
Venclexta	Venetoclax	11	330	$158,566
Eliquis	Apixaban	51	2,400	$47,170

Top 5 DME services in 2024

No connected or detailed DME service-level records for 2024.

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	13	$289	PFIZER INC.
Research Payments	Reported research-related payment or transfer-of-value amount.	0	$0	N/R
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Vinaya Potluri, M.D.?

Tedicare shows public-source Medicare data for Vinaya Potluri, M.D. (NPI 1881647493), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Vinaya Potluri, M.D. have ACO affiliation data?

Vinaya Potluri, M.D. is shown with ACO affiliation data for UT Southwestern Accountable Care Network (REACH, ACO ID D0211).

What billing organization is linked to Vinaya Potluri, M.D.?

Vinaya Potluri, M.D. is linked to ONCOLOGY-HEMATOLOGY CONSULTANTS PA (billing NPI 1629021159) in the available physician profile data.

Does Vinaya Potluri, M.D. have Open Payments data?

Vinaya Potluri, M.D. has 13 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.